Assoc. Prof. Dr. Shi-liang Huang | Tumor | Best Researcher Award

Assoc. Prof. Dr. Shi-liang Huang | Tumor | Best Researcher Award

Sun Yat-sen University | China

AUTHOR PROFILE

Scopus

ORCID ID

πŸ§‘β€πŸ”¬ DR. SHI-LIANG HUANG

Associate Professor in Medicinal Chemistry
Sun Yat-sen University, People’s Republic of China

🎯 OBJECTIVE

Dedicated Associate Professor specializing in Medicinal Chemistry, with a passion for driving innovation in drug discovery and development, focusing on the tumor microenvironment and the heat shock response.

πŸ“˜ EARLY ACADEMIC PURSUITS

Dr. Huang’s academic journey began with a solid foundation in Chemistry and Biochemistry, laying the groundwork for a distinguished career. After excelling in undergraduate studies, Dr. Huang pursued advanced degrees in Medicinal Chemistry, demonstrating exceptional aptitude for research and innovation.

Key achievements during this phase include:

  • Master’s Thesis: Groundbreaking work on natural product derivatives for therapeutic applications.
  • Doctoral Research: Advanced studies on the mechanisms of small molecules in altering biochemical pathways.

🏒 PROFESSIONAL ENDEAVORS

As an Associate Professor at Sun Yat-sen University, Dr. Huang has significantly contributed to the university’s reputation as a leading institution in medicinal research. His professional journey is marked by:

  • Leading Interdisciplinary Teams: Collaborating with experts in oncology, biochemistry, and computational modeling.
  • Research Innovation: Pioneering techniques in synthesizing inhibitors targeting heat shock proteins (HSPs) and heat shock factor 1 (HSF1).
  • Teaching Excellence: Mentoring students in natural medicinal chemistry and drug design methodologies.

πŸ§ͺ CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Huang’s work revolves around integrating bioorganic chemistry with tumor microenvironment studies to innovate cancer therapies. Key contributions include:

  • Medicinal Chemistry: Developing novel molecules with high specificity for cancer-related targets.
  • Natural Product Exploration: Isolating and modifying natural compounds to enhance their therapeutic potential.
  • Heat Shock Response Modulation: Designing inhibitors to disrupt HSF1 and HSP pathways, which are critical in cancer cell survival under stress.
  • Tumor Microenvironment Studies: Investigating how microenvironmental factors influence drug efficacy.

🌟 IMPACT AND INFLUENCE

Dr. Huang’s research has had a profound impact on the scientific community and beyond:

  • Published Works: Author of numerous peer-reviewed articles in high-impact journals.
  • Citations and Recognition: Garnered widespread academic citations, reflecting the influence and applicability of his research.
  • Collaboration and Leadership: Actively involved in global collaborations, enhancing the translational impact of his findings.

πŸ“Š ACADEMIC CITATIONS AND METRICS

Dr. Huang’s academic metrics underscore his scholarly contributions:

  • H-Index: Demonstrates significant citation impact in medicinal chemistry and oncology.
  • Published Articles: Over 50 research papers, including breakthroughs in bioorganic and natural medicinal chemistry.
  • Research Grants: Secured funding for multiple national and international projects.

πŸ† LEGACY AND FUTURE CONTRIBUTIONS

As a visionary in drug discovery, Dr. Huang aspires to expand his research impact by:

  • Advancing precision medicine approaches tailored to the tumor microenvironment.
  • Developing next-generation inhibitors targeting stress-response proteins in cancer therapy.
  • Mentoring the next wave of researchers in innovative medicinal chemistry.

🌏 CONCLUSION

Dr. Shi-liang Huang embodies a blend of academic rigor, research innovation, and educational leadership. His contributions continue to shape the future of medicinal chemistry, with a legacy that inspires collaboration, discovery, and impactful solutions in cancer therapy.

πŸ“ŠπŸ”¬NOTABLE PUBLICATION:
  • A Novel HSF1 Activator Ameliorates Non-Alcoholic Steatohepatitis by Stimulating Mitochondrial Adaptive Oxidation
    • Authors: Rao, Y.; Li, C.; Hu, Y.-T.; Ye, J.-M.; Huang, Z.-S.
    • Journal: British Journal of Pharmacology
    • Year: 2022

 

  • Design, Synthesis, and Evaluation of New Sugar-Substituted Imidazole Derivatives as Selective c-MYC Transcription Repressors Targeting the Promoter G-Quadruplex
    • Authors: Li, M.-L.; Yuan, J.-M.; Yuan, H.; Chen, S.-B.; Huang, Z.-S.
    • Journal: Journal of Medicinal Chemistry
    • Year: 2022

 

  • Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy
    • Authors: Pan, X.; Mao, T.-Y.; Mai, Y.-W.; Huang, Z.-S.; Huang, S.-L.
    • Journal: Molecules
    • Year: 2022

 

  • Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer
    • Authors: Jiang, X.-C.; Tu, F.-H.; Wei, L.-Y.; Chen, S.-B.; Huang, Z.-S.
    • Journal: Journal of Medicinal Chemistry
    • Year: 2022

 

  • Design and Synthesis of Bouchardatine Derivatives as a Novel AMP-Activated Protein Kinase Activator for the Treatment of Colorectal Cancer
    • Authors: Xu, Y.-H.; Hu, Y.-T.; Xu, S.-M.; Chen, S.-B.; Huang, Z.-S.
    • Journal: Journal of Medicinal Chemistry
    • Year: 2023

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Stanford University School of Medicine | United States

Author Profile

Scopus

Orcid id

πŸ“š Biography: Dr. Stavros Melemenidis

πŸŽ“ Education

  • DPhil in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2010-2015)
    • Mentors: Prof. Nicola Sibson, Prof. Ruth Muschel
    • Thesis: Development of molecular targeted imaging methods for the detection of lung metastasis and angiogenesis
  • M.Sc. in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2009-2010)
  • M.Sc. in Radiometrics – University of Liverpool, Dept. Physics, Liverpool, UK (2008-2009)
  • B.Sc. in Physics: Medical Applications – University of Liverpool, Dept. Physics, Liverpool, UK (2005-2008)
  • A.Eng. in PC Systems and Peripheral Equipment – IIEK Neapoleos, Technical College, Thessaloniki, Greece (1998-2000)
  • Cert. Medical Physics – UCLA, Dept. Radiation Oncology, Los Angeles, CA, USA (2022-2023)

🏒 Current Position

  • Director of Pre-clinical Radiotherapy – Dept. of Radiation Oncology, Stanford University (Jan 2023-present)
  • Research Scientist – Div. of Radiation Therapy, Stanford University (Feb 2020-present)

πŸ”¬ Research Experience & Skills

  • Stanford University, Dept. Radiation Oncology, Stanford, CA
    • Director of Pre-clinical Radiotherapy Core (Jun 2023-present)
      • Calibration of preclinical orthovoltage irradiators
      • Monthly and annual quality checks for dosimetric consistency
      • Innovation in animal radiation shielding via 3D design and additive manufacturing
    • Basic Life Research Scientist at Div. of Radiation Therapy (Jun 2020-present)
      • Pioneering preclinical ultra-high dose-rate (FLASH) irradiation experiments
      • Specializing in 3D-designed radiation shielding for animal safety
      • Expertise in dosimetry using radiochromic film and ion chambers
      • Development of animal models involving tumor implantation and microsurgical techniques
    • Postdoctoral Fellow (Feb 2016-Jun 2020)
      • Advisor: Edward E. Graves
      • Led development of in vivo mouse tumor models integrating imaging, radiotherapy, and immunotherapy
      • Specialized in ultrasound-guided injection techniques
      • Conducted research into immune cell migration with a focus on macrophage imaging
      • Evaluated radioprotective strategies for healthy tissue through drug development
    • Postdoctoral Fellow at University of Oxford, Dept. Radiation Oncology (Jan 2015-Sep 2015)
      • Advisor: Nicola R. Sibson
      • Designed and evaluated innovative imaging probes for metastasis detection and angiogenesis visualization
      • Developed dual MRI/PET probe for metastasis and MRI probe for angiogenesis
      • Managed international research collaboration with Duke University

πŸ“œ Selected Publications

  • In vivo PET detection of lung micrometastasis by targeting endothelial VCAM-1. Int J Mol Sci, 2024.
  • Multi-institutional audit of FLASH and conventional dosimetry with a 3D-printed anatomically realistic mouse phantom. Int J Radiat Oncol Biol Phys, 2023.
  • Exploring deep learning for estimating the isoeffective dose of FLASH irradiation from mouse intestinal histological images. J Radiat Oncol Biol Phys, 2023.
  • Human enteroids as a tool to study conventional and ultra-high dose rate radiation. Integr Biol (Camb), 2023.
  • Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. J Clin Invest, 2023.

πŸ† Awards & Honors

  • Recognition of Excellent Research: Aegean Conferences: 12th International Conference on Complement Therapeutics, Rhodes, Greece, 2019
  • Poster Prize: Aegean Conferences: 3rd International Conference for Tumor Microenvironment and Cellular Stress, Greece, Mykonos, 2014

πŸ—£οΈ Conference Presentations

  • Oral Presentation: Demonstrating FLASH effectiveness against CONV dose rates, 34th ACRO Summit, Orlando, FL, March 2024
  • Poster Presentation: Anatomically Realistic 3D Printed Mouse Phantom for Multi-Institutional Benchmarking of FLASH and CONV Irradiation, 65th ASTRO Annual Meeting San Diego, USA, Oct 2023

πŸ“ž References

  • Prof. Billy W Loo Jr: Professor of Radiation Oncology (Radiation Therapy), Stanford University School of Medicine
  • Prof. Edward E Graves: Associate Professor of Radiation Oncology and Director of Molecular Imaging Program, Stanford University School of Medicine
  • Prof. Frederick M Dirbas: Associate Professor of Surgery (General Surgery), Stanford University School of Medicine

Dr. Stavros Melemenidis is a distinguished figure in radiation oncology, with a profound impact on preclinical radiotherapy and FLASH irradiation research. His contributions to innovative imaging techniques and his dedication to advancing cancer treatment methodologies are reflected in his extensive publication record and numerous accolades.

πŸ“ŠπŸ”¬Notable Publication: